A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma. Read more about A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.
Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer. Read more about Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer.
Plexiform neurofibromas, trial design, and the definitions of "progression" and "treatment failure". Read more about Plexiform neurofibromas, trial design, and the definitions of "progression" and "treatment failure".
"We will know it when we see it;" bevacizumab and glioblastoma. Read more about "We will know it when we see it;" bevacizumab and glioblastoma.
Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma. Read more about Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma.
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Read more about Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
Getting more out of radiation therapy in glioblastoma. Read more about Getting more out of radiation therapy in glioblastoma.
BRAFV600E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Read more about BRAFV600E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors.
Lactate dehydrogenase A silencing in IDH mutant gliomas. Read more about Lactate dehydrogenase A silencing in IDH mutant gliomas.
Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Read more about Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial.
